Home » AGEB Journal » Issues » Volume 68" » Fasc.3 - Book review » Article details

BOOK REVIEW

Journal Volume 68 - 2005
Issue Fasc.3 - Book review
Author(s) A.P. Geubel.
Full article
Full Article
VIEW FREE PDF
Rifaximin : A Poorly Absorbed Antibiotic. Pharmacology and Clinical Use. Scarpignato C. (Edited by -). Karger, Basel, 2005.

Rifaximin is a semisynthetic rifamycin first described in1982. It is minimally absorbed by the normal gas- trointestinal tract and which has been recently approved by the FDA in the US for the treatment of traveler's diar- rhea. In Europe, it is likely available only into the italian market. Its antimicrobial activity is broad, mainly against gram-positive bacteria including oxacillin- resistant strains of Staphylococcus aureus, C. difficile and Helicobacter pylori.

© Acta Gastro-Enterologica Belgica.